SCHEMBL2345355

SCHEMBL2345355

CCOC(=O)c1ccc(-c2cc(NC(=O)c3cccn3C)ccc2C)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.49
MAPT P10636 5/20 0.48
RAB9A P51151 6/20 0.48
SMN1; SMN2 Q16637 5/20 0.48
NPC1 O15118 5/20 0.48
ALDH1A1 P00352 3/20 0.48
KMT2A Q03164 3/20 0.48
GAA P10253 2/20 0.48
MEN1 O00255 2/20 0.48
MAPK14 Q16539 2/20 0.45
PKM P14618 2/20 0.45
MAPK1 P28482 1/20 0.45
NFKB1 P19838 1/20 0.45
NFKB2 Q00653 1/20 0.45
RELA Q04206 1/20 0.45
GRM1 Q13255 1/20 0.44
NPSR1 Q6W5P4 1/20 0.43
TRPV1 Q8NER1 1/20 0.43
POLB P06746 1/20 0.43
LMNA P02545 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2348948 0.86 MAPK14 (0.49) RAB9ANPC1KMT2AMAPK14GRM1
SCHEMBL1639776 0.81 NPSR1 (0.64) MAPTRAB9ASMN1; SMN2NPC1ALDH1A1
SCHEMBL2350063 0.81 MAPK14 (0.64) MAPTRAB9ASMN1; SMN2NPC1ALDH1A1
SCHEMBL2347535 0.78 HSD17B10 (0.67) KDM4EMAPTRAB9ASMN1; SMN2NPC1
SCHEMBL23830417 0.75 SIRT2 (0.51) MAPTSMN1; SMN2POLB
SCHEMBL3926783 0.75 RAB9A (0.73) RAB9ASMN1; SMN2NPC1ALDH1A1KMT2A
SCHEMBL2349306 0.75 PDK1 (0.46) KDM4EMAPTRAB9ASMN1; SMN2NPC1
SCHEMBL2914495 0.75 HSD17B10 (0.62) KDM4EMAPTRAB9ASMN1; SMN2NPC1
SCHEMBL2352743 0.75 MAPT (0.58) MAPTRAB9ASMN1; SMN2NPC1ALDH1A1
SCHEMBL2349197 0.73 ALDH1A1 (0.76) KDM4EMAPTRAB9ASMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8008303-B2 e.g. 6-Methyl-biphenyl-3,4'-dicarboxylic acid 4'-[(3-bromo-phenyl)-amide]-[(4 morpholin-4-yl-phenyl)-amide]; viricide; with other active viricide such as interferon or ribavirin ASTRAZENECA AB (SE) 2011-08-30 US disclosed
EP-1940786-B1 BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C ARROW THERAPEUTICS LTD (GB) 2010-08-18 EP disclosed
US-20080255105-A1 Biphenyl Derivatives and Their Use in Treating Hepatitis C ARROW THERAPEUTICS LIMITED (GB) 2008-10-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255105-A1 Biphenyl Derivatives and Their Use in Treating Hepatitis C NR4A1, NR0B1, NR1H4 KDM4E 4293/4885MAPT 4798/4885RAB9A 1870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.